Celia Diez de los Rios, Lecturer at the University of Navarra, Spain, Board Member at From Testing to Targeted Treatments (FT3), Oncology Advanced Nurse Practitioner, Research Fellow at the University of Glasgow, shared a post on LinkedIn:
“Genomics is often described in technical language: variants, trees, sequencing, risk stratification.
But anyone working with Lynch syndrome knows that genetics is never only about one person.
It is about families, conversations, and decisions that move across generations.
On Lynch Syndrome Awareness Day, I keep thinking about how different this experience is from many other areas of oncology. A diagnosis does not end with treatment planning, it begins a long process of understanding risk, prevention, surveillance, and communication with relatives who may also be affected.
Behind every genomic test are questions patients ask quietly:
- What does this mean for my children?
- Who else in my family should know?
- How do I live with risk that I cannot see?
Oncology nurses frequently are there translating complex genomic information into understanding, supporting emotional adaptation, and helping families navigate uncertainty with clarity and compassion. Not only explaining results, but helping people integrate them into real life.
As genomic testing becomes more integrated into routine cancer care, our responsibility is not only to expand access, but to ensure care remains person and family centred.
We have worked hard in the special edition of hereditary cancer at Seminars in Oncology Nursing and to have many different authors collaborating and adding knowledge about hereditary cancer.
Thank you to each author and special thank you to the team of co-guest editors Memnun Seven, Celia Diez de los Rios, Meghan Underhill with who had the amazing chance to work.”
Other articles about Lynch Syndrome on OncoDaily.